Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN
  • CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
5:24 MIN
  • CIDP

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

DOWNLOAD PDF
Fatigue in CIDP
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
09:29 MIN
  • CIDP
Engage in a presentation on the comparison between active and remission disease states in CIDP.
DOWNLOAD PDF
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
15:31 MIN
  • CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
DOWNLOAD PDF
NOW PLAYING
14:01
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

NOW PLAYING
5:24
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

NOW PLAYING
09:29
Fatigue in CIDP
Engage in a presentation on the comparison between active and remission disease states in CIDP.
NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Our Experts on CIDP

Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • CIDP
  • GBS
  • MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
  • CIDP
  • GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

  • CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
PDF | 250 KB
Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
PDF | 2 MB
Incidence of GBS and CIDP Following Influenza Vaccination
PDF | 155 KB
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-...
PDF | 3.8 MB
Back to Top